Viking Therapeutics to Release Q1 2026 Financial Results and Host Conference Call
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 22 2026
0mins
Source: PRnewswire
- Earnings Release Schedule: Viking Therapeutics plans to release its Q1 2026 financial results after market close on April 29, 2026, showcasing advancements in therapies for metabolic and endocrine disorders, which may impact investor confidence.
- Conference Call Details: The company will host a conference call at 4:30 p.m. ET on April 29, 2026, to discuss financial results and corporate updates, providing a direct communication channel between investors and management to enhance transparency.
- Clinical Trial Progress: Viking is conducting Phase 3 trials for VK2735 aimed at treating obesity, with preliminary data indicating good safety and tolerability, which, if successful, could significantly enhance the company's competitive position in the metabolic disease treatment market.
- New Drug Development Updates: VK2809 has shown significant efficacy in a Phase 2 trial for non-alcoholic fatty liver disease, and if further validated, it could open new revenue streams for the company and strengthen its market position.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VKTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VKTX
Wall Street analysts forecast VKTX stock price to rise
12 Analyst Rating
12 Buy
0 Hold
0 Sell
Strong Buy
Current: 28.450
Low
70.00
Averages
97.00
High
125.00
Current: 28.450
Low
70.00
Averages
97.00
High
125.00
About VKTX
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for the treatment of metabolic and endocrine disorders. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. It is evaluating an oral formulation of VK2735 in a Phase II trial. It is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Buffett's Investment Strategy and Healthcare Opportunities
- Investment Legacy: Warren Buffett has led Berkshire Hathaway to market-beating returns over 60 years by focusing on industries and companies with competitive advantages, and new CEO Greg Abel has pledged to continue this investment philosophy.
- Healthcare Sector Absence: Despite a diverse portfolio, Berkshire Hathaway is almost entirely absent from the healthcare sector, holding only kidney care giant DaVita, which Buffett added in 2011, while Abel closed the position in UnitedHealth Group in Q1 this year.
- Healthcare Investment Opportunities: The healthcare industry offers a wide range of investment options, with aggressive investors potentially targeting high-growth pharmaceutical companies like Eli Lilly, while conservative investors may prefer dividend-paying companies like Johnson & Johnson and Abbott Laboratories for steady earnings growth.
- Independent Investment Decisions: While it is valuable to follow the investment decisions of Buffett and Abel, investors should also consider the high-potential healthcare sector and make independent investment choices to capitalize on growth opportunities in this field.
See More
Buffett and Abel's Investment Strategies
- Investment Legacy: Warren Buffett has led Berkshire Hathaway to market-beating returns over the past sixty years, and new CEO Greg Abel promises to continue this successful path, demonstrating stability and continuity in the company's leadership.
- Portfolio Analysis: Berkshire Hathaway's largest holding is Apple, and although Buffett typically avoids tech stocks, he opened a position in Alphabet last year, with Abel increasing it in Q1 this year, indicating a cautious interest in the tech sector.
- Healthcare Sector Absence: Despite a diverse portfolio, the healthcare sector is almost entirely absent, with only DaVita added in 2011, and Abel closing the position in UnitedHealth Group in Q1, reflecting a potential missed growth opportunity in this vital industry.
- Independent Investor Thinking: While Buffett and Abel's investment strategies are worth following, investors should make independent decisions based on their own needs and resources, as the healthcare sector offers diverse investment opportunities, particularly in biotech and pharmaceuticals, which could yield significant returns.
See More
Viking Therapeutics' VK2735 Phase 3 Trials Outlook
- Clinical Trial Progress: Viking Therapeutics' VK2735 is currently in Phase 3 trials, with investors hopeful for its efficacy and safety, particularly as it competes against larger rivals Eli Lilly and Novo Nordisk, raising interest in its market share potential.
- Comparative Drug Advantage: In Phase 2 trials, VK2735's injectable form achieved a peak weight loss of 14.7% over 13 weeks, outperforming competitors, which highlights its significant advantage in weight loss speed and may attract more patients.
- Tolerability Challenges: Despite VK2735's strong weight loss results, the oral formulation showed disappointing tolerability with a 20% treatment discontinuation rate, raising concerns about its long-term safety and potentially affecting market acceptance.
- Dual-Formulation Development: VK2735 is also being developed as a dual-formulation therapy, with Phase 1 trial results expected in Q3; if proven effective, this could provide Viking Therapeutics with additional competitive edge, although it still needs to address tolerability issues.
See More
Viking Therapeutics Faces Competitive Challenges in Weight-Loss Market
- Intensifying Market Competition: Viking Therapeutics' VK2735 faces fierce competition in the weight-loss drug market from Eli Lilly and Novo Nordisk, particularly with Novo Nordisk's oral Wegovy and Eli Lilly's Foundayo, which is projected to reach $1.2 billion in sales by 2026, highlighting significant market potential.
- Clinical Trial Progress: VK2735 is currently in Phase 3 trials, and while it demonstrated a 14.7% weight loss in Phase 2, the oral formulation showed poor tolerability with a 20% treatment discontinuation rate due to adverse events, which may hinder its market acceptance.
- Dual-Formulation Advantage: VK2735 is being developed as a dual-formulation therapy, with Phase 1 trial results expected in Q3; if proven effective, this could provide Viking with a crucial market share advantage in a competitive landscape.
- Uncertain Future Outlook: Although bulls hope that Phase 3 trials will demonstrate better tolerability and weight loss results, Viking must overcome its lag behind two larger rivals to secure a foothold in the weight-loss drug market.
See More
Viking Therapeutics Faces Challenges and Opportunities Ahead
- Stock Volatility: Viking Therapeutics (VKTX) shares fell 6% on Tuesday, marking its worst single-day drop since late March, and are on track for the worst week since November, reflecting market concerns over upcoming trial data.
- Clinical Trial Progress: The data readout from VKTX's maintenance dosing study is expected in Q3, involving 180 patients to test whether VK2735 can maintain weight loss with less frequent dosing while minimizing side effects; positive results could significantly enhance the company's competitive edge in the obesity drug market.
- Analyst Sentiment: Despite the stock's decline, Wall Street remains bullish, with 18 out of 20 analysts rating VKTX as 'Buy' or higher, and a 12-month average price target of $92.58, indicating a potential upside of about 216%, showcasing confidence in the company's future growth prospects.
- Strong Cash Position: As of the end of Q1, Viking Therapeutics had a cash runway of $603 million, sufficient to fund its clinical trials and R&D plans into 2027, bolstering its resilience in the highly competitive obesity treatment market.
See More
Investment Case for Viking Therapeutics' VK2735 Weight-Loss Drug Development
- Clinical Trial Progress: Viking Therapeutics' VK2735 is undergoing a Phase 1 maintenance clinical trial involving approximately 180 participants, with results expected in Q3 this year, which could significantly influence investor perceptions of the stock.
- Comparative Efficacy Advantage: VK2735 demonstrated a 12.2% mean weight loss in the Phase 2 Venture oral trial after 13 weeks, suggesting potential superiority over Novo Nordisk's Wegovy, which achieved 16.6% weight loss over 64 weeks, indicating VK2735's oral formulation may be more effective.
- Safety and Tolerability Considerations: Despite VK2735's promising weight loss results, a 20% discontinuation rate due to adverse events in the Phase 2 trial highlights the need for further validation of safety and tolerability to bolster confidence in Phase 3 trials.
- Market Competitive Outlook: Should VK2735 demonstrate superior efficacy and safety in upcoming Phase 3 trials compared to Eli Lilly and Novo Nordisk's offerings, Viking could gain a competitive edge by offering a regimen that combines initial subcutaneous dosing followed by oral administration, potentially driving stock price increases.
See More
Buffett's Investment Strategy and Healthcare Opportunities
- Investment Legacy: Warren Buffett has led Berkshire Hathaway to market-beating returns over 60 years by focusing on industries and companies with competitive advantages, and new CEO Greg Abel has pledged to continue this investment philosophy.
- Healthcare Sector Absence: Despite a diverse portfolio, Berkshire Hathaway is almost entirely absent from the healthcare sector, holding only kidney care giant DaVita, which Buffett added in 2011, while Abel closed the position in UnitedHealth Group in Q1 this year.
- Healthcare Investment Opportunities: The healthcare industry offers a wide range of investment options, with aggressive investors potentially targeting high-growth pharmaceutical companies like Eli Lilly, while conservative investors may prefer dividend-paying companies like Johnson & Johnson and Abbott Laboratories for steady earnings growth.
- Independent Investment Decisions: While it is valuable to follow the investment decisions of Buffett and Abel, investors should also consider the high-potential healthcare sector and make independent investment choices to capitalize on growth opportunities in this field.
See More
Buffett and Abel's Investment Strategies
- Investment Legacy: Warren Buffett has led Berkshire Hathaway to market-beating returns over the past sixty years, and new CEO Greg Abel promises to continue this successful path, demonstrating stability and continuity in the company's leadership.
- Portfolio Analysis: Berkshire Hathaway's largest holding is Apple, and although Buffett typically avoids tech stocks, he opened a position in Alphabet last year, with Abel increasing it in Q1 this year, indicating a cautious interest in the tech sector.
- Healthcare Sector Absence: Despite a diverse portfolio, the healthcare sector is almost entirely absent, with only DaVita added in 2011, and Abel closing the position in UnitedHealth Group in Q1, reflecting a potential missed growth opportunity in this vital industry.
- Independent Investor Thinking: While Buffett and Abel's investment strategies are worth following, investors should make independent decisions based on their own needs and resources, as the healthcare sector offers diverse investment opportunities, particularly in biotech and pharmaceuticals, which could yield significant returns.
See More
Viking Therapeutics' VK2735 Phase 3 Trials Outlook
- Clinical Trial Progress: Viking Therapeutics' VK2735 is currently in Phase 3 trials, with investors hopeful for its efficacy and safety, particularly as it competes against larger rivals Eli Lilly and Novo Nordisk, raising interest in its market share potential.
- Comparative Drug Advantage: In Phase 2 trials, VK2735's injectable form achieved a peak weight loss of 14.7% over 13 weeks, outperforming competitors, which highlights its significant advantage in weight loss speed and may attract more patients.
- Tolerability Challenges: Despite VK2735's strong weight loss results, the oral formulation showed disappointing tolerability with a 20% treatment discontinuation rate, raising concerns about its long-term safety and potentially affecting market acceptance.
- Dual-Formulation Development: VK2735 is also being developed as a dual-formulation therapy, with Phase 1 trial results expected in Q3; if proven effective, this could provide Viking Therapeutics with additional competitive edge, although it still needs to address tolerability issues.
See More
Viking Therapeutics Faces Competitive Challenges in Weight-Loss Market
- Intensifying Market Competition: Viking Therapeutics' VK2735 faces fierce competition in the weight-loss drug market from Eli Lilly and Novo Nordisk, particularly with Novo Nordisk's oral Wegovy and Eli Lilly's Foundayo, which is projected to reach $1.2 billion in sales by 2026, highlighting significant market potential.
- Clinical Trial Progress: VK2735 is currently in Phase 3 trials, and while it demonstrated a 14.7% weight loss in Phase 2, the oral formulation showed poor tolerability with a 20% treatment discontinuation rate due to adverse events, which may hinder its market acceptance.
- Dual-Formulation Advantage: VK2735 is being developed as a dual-formulation therapy, with Phase 1 trial results expected in Q3; if proven effective, this could provide Viking with a crucial market share advantage in a competitive landscape.
- Uncertain Future Outlook: Although bulls hope that Phase 3 trials will demonstrate better tolerability and weight loss results, Viking must overcome its lag behind two larger rivals to secure a foothold in the weight-loss drug market.
See More
Viking Therapeutics Faces Challenges and Opportunities Ahead
- Stock Volatility: Viking Therapeutics (VKTX) shares fell 6% on Tuesday, marking its worst single-day drop since late March, and are on track for the worst week since November, reflecting market concerns over upcoming trial data.
- Clinical Trial Progress: The data readout from VKTX's maintenance dosing study is expected in Q3, involving 180 patients to test whether VK2735 can maintain weight loss with less frequent dosing while minimizing side effects; positive results could significantly enhance the company's competitive edge in the obesity drug market.
- Analyst Sentiment: Despite the stock's decline, Wall Street remains bullish, with 18 out of 20 analysts rating VKTX as 'Buy' or higher, and a 12-month average price target of $92.58, indicating a potential upside of about 216%, showcasing confidence in the company's future growth prospects.
- Strong Cash Position: As of the end of Q1, Viking Therapeutics had a cash runway of $603 million, sufficient to fund its clinical trials and R&D plans into 2027, bolstering its resilience in the highly competitive obesity treatment market.
See More
Investment Case for Viking Therapeutics' VK2735 Weight-Loss Drug Development
- Clinical Trial Progress: Viking Therapeutics' VK2735 is undergoing a Phase 1 maintenance clinical trial involving approximately 180 participants, with results expected in Q3 this year, which could significantly influence investor perceptions of the stock.
- Comparative Efficacy Advantage: VK2735 demonstrated a 12.2% mean weight loss in the Phase 2 Venture oral trial after 13 weeks, suggesting potential superiority over Novo Nordisk's Wegovy, which achieved 16.6% weight loss over 64 weeks, indicating VK2735's oral formulation may be more effective.
- Safety and Tolerability Considerations: Despite VK2735's promising weight loss results, a 20% discontinuation rate due to adverse events in the Phase 2 trial highlights the need for further validation of safety and tolerability to bolster confidence in Phase 3 trials.
- Market Competitive Outlook: Should VK2735 demonstrate superior efficacy and safety in upcoming Phase 3 trials compared to Eli Lilly and Novo Nordisk's offerings, Viking could gain a competitive edge by offering a regimen that combines initial subcutaneous dosing followed by oral administration, potentially driving stock price increases.
See More
